01
Dec
2008
Posted in I - Series D, Q - 3Q08, R - NORTH EAST, X - Biomarker, X - Device (Diagnostic)
BG Medicine (Waltham, MA) focused on the discovery, development and commercialization of molecular biomarkers and diagnostics, closed a $40M Series D financing. Participants include Legg Mason Capital Management, GE Asset Management, SmallCap World Fund, Flagship Ventures, Gilde Healthcare Partners, Humana, and Stelios Papadopoulos.